Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$5.71 - $13.15 $140,848 - $324,371
-24,667 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$8.56 - $27.17 $211,149 - $670,202
24,667 New
24,667 $347,000

Others Institutions Holding EFTR

About eFFECTOR Therapeutics, Inc.


  • Ticker EFTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,452,800
  • Description
  • eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-sma...
More about EFTR
Track This Portfolio

Track Verition Fund Management LLC Portfolio

Follow Verition Fund Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Verition Fund Management LLC with notifications on news.